Home Management Cachexia Bone Marrow Dyslipidemia Pipeline Contact Us


Pipeline

[The proposed human trials are based on the results described in seven issued US and international patents as well as three pending international patent applications.]



Candidate & Indication
Developmental Stage
Exit
Pre-clinical & Animal Toxicology
Human Toxicology
Phase 1
Phase 2
I. Test the value of blood test to predict future cachexia.
Use confirmed test to select patients for PLAP treatment
II. rPLAP for Phase 1 toxicology study with cancer patients.
Exit or move to Phase 2
III. rPLAP + chemotherapy for cancer treatments in Phase 2 trial checking for the expected outcomes:
1. Enhance cancer treatments,
2. Reduce muscle wasting,
3. Reduce loss of body weight, and
4. Protect bone marrow
Exit after Phase 2 trial
IV. PLAP with or without a statin on dyslipidemia
The project is on sale